Compare
Vyome Holdings, Inc vs Abvc Biopharma, Inc. vs Scienture Holdings, Inc. vs Clene Inc.
| Latest fiscal year | Vyome Holdings, Inc HIND | Abvc Biopharma, Inc. ABVC | Scienture Holdings, Inc. SCNX | Clene Inc. CLNN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $319.7K | $296.0K | $431.6K | $200.0K |
| Revenue growth (YoY) | +24.4% | -41.9% | +215.9% | -41.5% |
| Gross margin | 68.4% | n/a | 76.8% | 78.5% (computed) |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$10.26M | -$7.91M | -$41.51M | -$26.17M |
| EPS (Diluted) | -$4.86 | -$0.39 | -$2.70 | n/a |
| Operating cash flow | -$3.75M | -$2.99M | -$13.38M | -$18.55M |
| Free cash flow | n/a | n/a | n/a | -$18.59M |
| Cash & equivalents | $4.98M | $681.5K | $6.66M | $5.19M |
| Total assets | $6.50M | $21.06M | $84.18M | $18.13M |
| Total liabilities | $2.74M | $7.76M | $14.06M | $35.72M |
| Shareholders' equity | $3.76M | $11.11M | $70.12M | -$17.59M |
| Return on year-end equity | -272.8% | -71.2% | -59.2% | n/a |
| Shares outstanding | 5.92M | 25.05M | 40.63M | 10.85M |
Revenue, most recent five fiscal years
| Fiscal year | Vyome Holdings, Inc | Abvc Biopharma, Inc. | Scienture Holdings, Inc. | Clene Inc. |
|---|---|---|---|---|
| Latest | $319.7K Ended 2025-12-31 | $296.0K Ended 2025-12-31 | $431.6K Ended 2025-12-31 | $200.0K Ended 2025-12-31 |
| 1 year earlier | $256.9K Ended 2024-12-31 | $509.6K Ended 2024-12-31 | $136.6K Ended 2024-12-31 | $342.0K Ended 2024-12-31 |
| 2 years earlier | $8.68M Ended 2023-12-31 | n/a | $1.36M Ended 2023-12-31 | $654.0K Ended 2023-12-31 |
| 3 years earlier | $11.24M Ended 2022-12-31 | n/a | $10.25M Ended 2022-12-31 | $473.0K Ended 2022-12-31 |
| 4 years earlier | $13.60M Ended 2021-12-31 | n/a | $9.89M Ended 2021-12-31 | $723.0K Ended 2021-12-31 |